News
Bharat Biotech Successfully Ships out COVAXIN™ to 11 cities, donates 16.5 Lakh doses to the Government
Hyderabad, India, January 13, 2021: Bharat Biotech has announced the successful air-shipment of COVAXIN™, to 11 cities in India in the early hours of Wednesday. Bharat Biotech has also donated 16.5 Lakh doses to the Government of India.
Bharat Biotech’s ‘COVAXIN™’ Emergency Use Authorization approval by DCGI-CDSCO, MoH&FW, a significant landmark in India’s Scientific Discovery, and Scientists Capability
Dr. Krishna Ella said “The approval of COVAXIN™ for emergency use is a giant leap for Innovation and novel product development in India. It is a proud moment for the nation and a great milestone in India’s scientific capability, a kickstart to the innovation ecosystem in India. While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most. COVAXIN™ has generated excellent safety data with robust immune responses to multiple viral proteins that persist.”
COVAXIN phase 2 study results & Phase-1 follow Up data
COVAXIN™ (BBV152) showed long-term antibody and T-cell memory responses (3-months after vaccination) in phase 1 volunteers, and tolerable safety outcomes with enhanced humoral & cell-mediated immune responses in the Phase 2 study.
BioEconomy Conclave 2026
